RESUMEN
BACKGROUND AND AIMS: We aimed to characterize the epidemiologic and comorbidities profiles of patients with chronic Hepatitis D (CHD) followed in clinical practice in Italy and explored their interferon (IFN) eligibility. METHODS: This was a cross-sectional study of the PITER cohort consisting of consecutive HBsAg-positive patients from 59 centers over the period 2019-2023. Multivariable analysis was performed by logistic regression model. RESULTS: Of 5492 HBsAg-positive enrolled patients, 4152 (75.6%) were screened for HDV, 422 (10.2%) were anti-HDV positive. Compared with HBsAg mono-infected, anti-HDV positive patients were more often younger, non-Italians, with a history of drug use, had elevated alanine transaminase (ALT), cirrhosis, or hepatocellular carcinoma (HCC). Compared with Italians, anti-HDV positive non-Italians were younger (42.2% age ≤ 40 years vs. 2.1%; P < 0.001), more often females (males 43.0% vs. 68.6%; P < 0.001) with less frequent cirrhosis and HCC. HDV-RNA was detected in 63.2% of anti-HDV-positive patients, who were more likely to have elevated ALT, cirrhosis, and HCC. Extrahepatic comorbidities were present in 47.4% of anti-HDV positive patients and could affect the eligibility of IFN-containing therapies in at least 53.0% of patients in care. CONCLUSIONS: CHD affects young, foreign-born patients and older Italians, of whom two-thirds had cirrhosis or HCC. Comorbidities were frequent in both Italians and non-Italians and impacted eligibility for IFN.
Asunto(s)
Hepatitis D Crónica , Virus de la Hepatitis Delta , Humanos , Femenino , Masculino , Italia/epidemiología , Hepatitis D Crónica/epidemiología , Adulto , Persona de Mediana Edad , Estudios Transversales , Virus de la Hepatitis Delta/inmunología , Virus de la Hepatitis Delta/genética , Estudios de Cohortes , Cirrosis Hepática/epidemiología , Cirrosis Hepática/virología , Carcinoma Hepatocelular/epidemiología , Carcinoma Hepatocelular/virología , Comorbilidad , Anciano , Antígenos de Superficie de la Hepatitis B/sangre , Neoplasias Hepáticas/epidemiología , Neoplasias Hepáticas/virología , Interferones/uso terapéutico , Antivirales/uso terapéuticoRESUMEN
Importance: Hepatitis D virus (HDV) infection occurs in association with hepatitis B virus (HBV) infection and affects approximately 12 million to 72 million people worldwide. HDV causes more rapid progression to cirrhosis and higher rates of hepatocellular carcinoma than HBV alone or hepatitis C virus. Observations: HDV requires HBV to enter hepatocytes and to assemble and secrete new virions. Acute HDV-HBV coinfection is followed by clearance of both viruses in approximately 95% of people, whereas HDV superinfection in an HBV-infected person results in chronic HDV-HBV infection in more than 90% of infected patients. Chronic hepatitis D causes more rapidly progressive liver disease than HBV alone. Approximately 30% to 70% of patients with chronic hepatitis D have cirrhosis at diagnosis and more than 50% die of liver disease within 10 years of diagnosis. However, recent studies suggested that progression is variable and that more than 50% of people may have an indolent course. Only approximately 20% to 50% of people infected by hepatitis D have been diagnosed due to lack of awareness and limited access to reliable diagnostic tests for the HDV antibody and HDV RNA. The HBV vaccine prevents HDV infection by preventing HBV infection, but no vaccines are available to protect those with established HBV infection against HDV. Interferon alfa inhibits HDV replication and reduces the incidence of liver-related events such as liver decompensation, hepatocellular carcinoma, liver transplant, or mortality from 8.5% per year to 3.3% per year. Adverse effects from interferon alfa such as fatigue, depression, and bone marrow suppression are common. HBV nucleos(t)ide analogues, such as entecavir or tenofovir, are ineffective against HDV. Phase 3 randomized clinical trials of bulevirtide, which blocks entry of HDV into hepatocytes, and lonafarnib, which interferes with HDV assembly, showed that compared with placebo or observation, these therapies attained virological and biochemical response in up to 56% of patients after 96 weeks of bulevirtide monotherapy and 19% after 48 weeks of lonafarnib, ritonavir, and pegylated interferon alfa treatment. Conclusions and Relevance: HDV infection affects approximately 12 million to 72 million people worldwide and is associated with more rapid progression to cirrhosis and liver failure and higher rates of hepatocellular carcinoma than infection with HBV alone. Bulevirtide was recently approved for HDV in Europe, whereas pegylated interferon alfa is the only treatment available in most countries.
Asunto(s)
Coinfección , Hepatitis D Crónica , Humanos , Antivirales/efectos adversos , Antivirales/uso terapéutico , Carcinoma Hepatocelular/epidemiología , Carcinoma Hepatocelular/etiología , Carcinoma Hepatocelular/prevención & control , Coinfección/epidemiología , Coinfección/prevención & control , Coinfección/virología , Hepatitis B/complicaciones , Hepatitis B/tratamiento farmacológico , Hepatitis B/epidemiología , Virus de la Hepatitis B , Hepatitis D/complicaciones , Hepatitis D/diagnóstico , Hepatitis D/tratamiento farmacológico , Hepatitis D Crónica/complicaciones , Hepatitis D Crónica/diagnóstico , Hepatitis D Crónica/tratamiento farmacológico , Hepatitis D Crónica/epidemiología , Virus de la Hepatitis Delta/genética , Interferón-alfa/efectos adversos , Interferón-alfa/uso terapéutico , Cirrosis Hepática/epidemiología , Cirrosis Hepática/etiología , Cirrosis Hepática/virología , Neoplasias Hepáticas/epidemiología , Neoplasias Hepáticas/etiología , Neoplasias Hepáticas/prevención & control , Neoplasias Hepáticas/virología , Polietilenglicoles/efectos adversos , Polietilenglicoles/uso terapéuticoRESUMEN
INTRODUCTION: Chronic Hepatitis D virus (HDV) infection remains an important global public health problem, with a changing epidemiological landscape over the past decade along with widespread implementation of hepatitis B vaccination and human migration. The landscape of HDV treatments has been changing, with therapies that have been under development for the last decade now in late stage clinical trials. The anticipated availability of these new therapies will hopefully replace the current therapies which are minimally effective. AREAS COVERED: This narrative review discusses the clinical course, screening and diagnosis, transmission risk factors, epidemiology, current and investigational therapies, and liver transplantation in HDV. Literature review was performed using PubMed and ClinicalTrials.gov and includes relevant articles from 1977 to 2022. EXPERT OPINION: HDV infection is an important global public health issue with a true prevalence that is still unknown. The distribution of HDV infection has changed globally with the availability of HBV vaccination and patterns of human migration. As HDV infection is associated with accelerated disease courses and poor outcomes, the global community needs to agree upon a uniform HDV screening strategy to understand the truth of global prevalence such that new therapies can target appropriate individuals as they become available in the future.
Asunto(s)
Hepatitis B , Hepatitis D Crónica , Hepatitis D , Trasplante de Hígado , Humanos , Hepatitis D Crónica/tratamiento farmacológico , Hepatitis D Crónica/epidemiología , Hepatitis D/diagnóstico , Hepatitis D/tratamiento farmacológico , Hepatitis D/epidemiología , Virus de la Hepatitis Delta , Factores de Riesgo , Virus de la Hepatitis B , Hepatitis B/diagnóstico , Hepatitis B/tratamiento farmacológico , Hepatitis B/epidemiologíaRESUMEN
Hepatitis D virus (HDV) infection is a chronic viral disease of the liver that is still largely considered to be incurable due to lack of effective treatment options. Without treatment, the risk for the development of advanced liver disease, cirrhosis and hepatocellular carcinoma is significantly high. Currently, new therapeutic options are emerging out of ongoing phase 3 clinical trials, promising a new hope of cure for this devastating liver infection. Recently, bulevirtide, a first in its class HDV entry inhibitor, has received conditional authorization of use from the European Medicines Agency (EMA) and was also submitted for approval in the United States. Other novel therapeutic options in clincal trials include interferon lambda, the prenylation inhibitor lonafarnib and nucleic acidic polymers (NAPs). This review describes all recent advances and ongoing changes to the field of HDV therpaeutics.
Asunto(s)
Hepatitis D Crónica , Hepatitis D , Neoplasias Hepáticas , Antivirales/farmacología , Antivirales/uso terapéutico , Hepatitis D/tratamiento farmacológico , Hepatitis D/epidemiología , Hepatitis D Crónica/complicaciones , Hepatitis D Crónica/tratamiento farmacológico , Hepatitis D Crónica/epidemiología , Virus de la Hepatitis Delta , Humanos , Lipopéptidos , Neoplasias Hepáticas/tratamiento farmacológicoRESUMEN
The global epidemiology of hepatitis D is changing with the widespread implementation of vaccination against hepatitis B. In high-income countries that achieved optimal control of HBV, the epidemiology of hepatitis D is dual, consisting of an ageing cohort of domestic patients with advanced liver fibrosis who represent the end stage of the natural history of HDV, and of a younger generation of immigrants from endemic countries who account for the majority of new infections. As observed in Europe in the 1980s, the distinctive clinical characteristic of chronic hepatitis D in endemic countries is the accelerated progression to cirrhosis and hepatocellular carcinoma. Despite some recent progress, the therapeutic management of HDV remains unsatisfactory, as most patients are not cured of HDV with currently available medicines. This review article describes the current epidemiology and clinical features of chronic hepatitis D, based on the literature published in the last 10 years.
Asunto(s)
Antivirales/farmacología , Hepatitis D Crónica , Coinfección/epidemiología , Europa (Continente)/epidemiología , Hepatitis D Crónica/epidemiología , Hepatitis D Crónica/terapia , Hepatitis D Crónica/transmisión , Hepatitis D Crónica/virología , Humanos , Evaluación de NecesidadesAsunto(s)
Hepatitis C Crónica/epidemiología , Hepatitis D Crónica/epidemiología , Virus de la Hepatitis Delta/aislamiento & purificación , Necrosis Hepática Masiva/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Femenino , Hepacivirus/aislamiento & purificación , Anticuerpos Antihepatitis/aislamiento & purificación , Virus de la Hepatitis B/aislamiento & purificación , Hepatitis B Crónica/diagnóstico , Hepatitis B Crónica/virología , Hepatitis C Crónica/complicaciones , Hepatitis C Crónica/diagnóstico , Hepatitis C Crónica/virología , Hepatitis D Crónica/complicaciones , Hepatitis D Crónica/diagnóstico , Hepatitis D Crónica/virología , Virus de la Hepatitis Delta/genética , Virus de la Hepatitis Delta/inmunología , Humanos , Pueblos Indígenas/estadística & datos numéricos , Masculino , Necrosis Hepática Masiva/diagnóstico , Necrosis Hepática Masiva/virología , Persona de Mediana Edad , ARN Viral/aislamiento & purificación , Venezuela/epidemiología , Adulto JovenRESUMEN
BACKGROUND: Mongolia is a highly endemic region for chronic hepatitis B (HBV), hepatitis delta (HDV), and hepatitis C (HCV) infections. Aim of this study was to comprehensively characterize chronic viral hepatitis among Mongols living in Southern California. METHODS: Three screening events were conducted between August and November 2018, with 528 adult Mongols tested for HBV and HCV. HBsAg (+) individuals (CHB) underwent additional testing for HDV RNA and anti-HDV. Liver tests, platelet count, and FibroScan™ were performed on CHB and chronic HCV (CHC) individuals. RESULTS: Fifty-one out of 534 were HBsAg reactive (9.7%), and all were foreign-born. Mean age of CHB individuals was 37.8 (range 18-69) years. Forty-six out of 51 were HBeAg (-). HBV genotypes were exclusively D2 or A1. Twenty-one out of 51 (41.2%) were anti-HDV (+) and 17/51 (33.3%) were HDV RNA (+). HDV RNA (+) individuals had significantly higher ALT, fibrosis-4 score, and liver stiffness compared to HDV RNA (-) individuals. Incidence of advanced fibrosis was higher in HDV RNA (+) individuals (57% vs. 13%, p = 0.013). Forty-eight (9.1%) individuals were anti-HCV (+) and 19 (3.6%) were HCV RNA (+). Mean age of CHC individuals was 40.2 (range 28-71) years. Prevalence of anti-HCV (+) was higher among those born between 1945 and 1965 versus those born after 1965 (18.8% vs. 7.9%, p = 0.025). Genotype 1b was predominant. Incidence of cirrhosis was 7% among all participants. CONCLUSIONS: Mongols living in the USA are at high risk for CHB and CHC infections. One-third of CHB individuals had CHD superinfection with advanced fibrosis. Universal screening for viral hepatitis in Mongols in the USA is mandatory.
Asunto(s)
Hepatitis B Crónica/epidemiología , Hepatitis C Crónica/epidemiología , Hepatitis D Crónica/epidemiología , Cirrosis Hepática/epidemiología , Adolescente , Adulto , Anciano , Anticuerpos Antivirales/sangre , Pueblo Asiatico , Estudios Transversales , Femenino , Genotipo , Virus de la Hepatitis B/genética , Hepatitis B Crónica/complicaciones , Hepatitis C Crónica/complicaciones , Hepatitis D Crónica/complicaciones , Humanos , Cirrosis Hepática/etiología , Masculino , Persona de Mediana Edad , Mongolia , ARN Viral/sangre , Adulto JovenRESUMEN
In this study, we investigated the seroprevalence of anti-hepatitis D virus (HDV) antibodies in hepatitis B surface antigen (HBsAg)-positive children after 25 years of obligatory vaccination of infants against hepatitis B virus. This cross-sectional study included 120 treatment-naïve HBsAg-positive children, with a male-to-female ratio of 1.8:1 and a mean age of 7.8 ± 3.8 years (range, 1-17 years). Mothers were positive for HBsAg in 96.6% of the cases. HBeAg-positive chronic infection was observed in 60% of the cases, HBeAg-positive chronic hepatitis in 12.5%, and HBeAg-negative chronic infection in 26.7%. Anti-HDV antibodies were not detected in any of the cases. Thus, there is a lack of anti-HDV antibodies in HBsAg-positive children, despite the current burden in adults.
Asunto(s)
Anticuerpos Antihepatitis/sangre , Antígenos de Superficie de la Hepatitis B/sangre , Vacunas contra Hepatitis B/administración & dosificación , Virus de la Hepatitis B/inmunología , Hepatitis B/epidemiología , Hepatitis D Crónica/epidemiología , Virus de la Hepatitis Delta/inmunología , Adolescente , Niño , Preescolar , Coinfección , Estudios Transversales , Egipto/epidemiología , Femenino , Hepatitis B/inmunología , Hepatitis B/prevención & control , Hepatitis B/virología , Virus de la Hepatitis B/efectos de los fármacos , Virus de la Hepatitis B/patogenicidad , Hepatitis D Crónica/sangre , Hepatitis D Crónica/inmunología , Hepatitis D Crónica/virología , Virus de la Hepatitis Delta/patogenicidad , Humanos , Lactante , Masculino , Estudios SeroepidemiológicosRESUMEN
PURPOSE OF REVIEW: Limited data exist on the prevalence, determinants, and outcomes of hepatitis delta virus (HDV) infection among HIV/hepatitis B virus (HBV)-coinfected persons. This review provides current evidence on the epidemiology, natural history, and treatment of HDV infection in patients with HIV/HBV coinfection and highlights future research needs. RECENT FINDINGS: Cross-sectional studies in Europe, Africa, South America, and Asia show that the prevalence of HDV among HIV/HBV-coinfected patients ranges from 1.2 to 25%. No studies have evaluated the prevalence of HDV infection among HIV/HBV-coinfected patients in the USA. HDV infection increases the risk of hepatic decompensation and hepatocellular carcinoma among HIV/HBV-coinfected patients. HDV treatment remains limited to pegylated interferon-alpha, which results in sustained virologic response in fewer than 25%. Data on the epidemiology, natural history, and treatment of HDV among HIV/HBV-coinfected persons remain limited. More research is needed to address these knowledge gaps in order to better manage HDV coinfection in HIV/HBV-coinfected patients.
Asunto(s)
Antivirales/uso terapéutico , Infecciones por VIH/epidemiología , Hepatitis B Crónica/tratamiento farmacológico , Hepatitis B Crónica/epidemiología , Hepatitis D Crónica/tratamiento farmacológico , Hepatitis D Crónica/epidemiología , Adulto , África , Asia , Carcinoma Hepatocelular/epidemiología , Carcinoma Hepatocelular/virología , Coinfección/tratamiento farmacológico , Coinfección/virología , Estudios Transversales , Europa (Continente) , Femenino , Infecciones por VIH/tratamiento farmacológico , Virus de la Hepatitis B/efectos de los fármacos , Hepatitis D Crónica/patología , Virus de la Hepatitis Delta/efectos de los fármacos , Humanos , Interferón alfa-2/uso terapéutico , Interferón-alfa/uso terapéutico , Hígado/patología , Neoplasias Hepáticas/epidemiología , Neoplasias Hepáticas/virología , Masculino , Polietilenglicoles/uso terapéutico , Prevalencia , Proteínas Recombinantes/uso terapéutico , Respuesta Virológica SostenidaRESUMEN
BACKGROUND & AIMS: HDV infection causes severe chronic liver disease in individuals infected with HBV. However, the factors associated with poor prognosis are largely unknown. Thus, we aimed to identify prognostic factors in patients with HDV infection. METHODS: The French National Reference Centre for HDV performed a nationwide retrospective study on 1,112 HDV-infected patients, collecting epidemiological, clinical, virological and histological data from the initial referral to the last recorded follow-up. RESULTS: The median age of our cohort was 36.5 (29.9-43.2) years and 68.6% of our cohort were male. Most patients whose birthplace was known were immigrants from sub-Saharan Africa (52.5%), southern and eastern Europe (21.3%), northern Africa and the Middle East (6.2%), Asia (5.9%) and South America (0.3%). Only 150 patients (13.8%) were French native. HDV load was positive in 659 of 748 tested patients (88.1%). HDV-1 was predominant (75.9%), followed by sub-Saharan genotypes: HDV-5 (17.6%), HDV-7 (2.9%), HDV-6 (1.8%) and HDV-8 (1.6%). At referral, 312 patients (28.2%) had cirrhosis, half having experienced at least 1 episode of hepatic decompensation. Cirrhosis was significantly less frequent in African than in European patients regardless of HDV genotype. At the end of follow-up (median 3.0 [0.8-7.2] years), 48.8% of the patients had developed cirrhosis, 24.2% had ≥1 episode(s) of decompensation and 9.2% had hepatocellular carcinoma. European HDV-1 and African HDV-5 patients were more at risk of developing cirrhosis. Persistent replicative HDV infection was associated with decompensation, hepatocellular carcinoma and death. African patients displayed better response to interferon therapy than non-African patients (46.4% vs. 29.1%, p <0.001). HDV viral load at baseline was significantly lower in responders than in non-responders. CONCLUSION: Place of birth, HDV genotype and persistent viremia constitute the main determinants of liver involvement and response to treatment in chronic HDV-infected patients. LAY SUMMARY: Chronic liver infection by hepatitis delta virus (HDV) is the most severe form of chronic viral hepatitis. Despite the fact that at least 15-20 million people are chronically infected by HDV worldwide, factors determining the severity of liver involvement are largely unknown. By investigating a large cohort of 1,112 HDV-infected patients followed-up in France, but coming from different areas of the world, we were able to determine that HDV genotype, place of birth (reflecting both viral and host-related factors) and persistent viremia constitute the main determinants of liver involvement and response to treatment.
Asunto(s)
Carcinoma Hepatocelular , Hepatitis D Crónica , Virus de la Hepatitis Delta , Cirrosis Hepática , Neoplasias Hepáticas , Viremia , Adulto , Carcinoma Hepatocelular/etnología , Carcinoma Hepatocelular/patología , Carcinoma Hepatocelular/virología , Femenino , Francia/epidemiología , Hepatitis D Crónica/complicaciones , Hepatitis D Crónica/diagnóstico , Hepatitis D Crónica/epidemiología , Hepatitis D Crónica/terapia , Virus de la Hepatitis Delta/genética , Virus de la Hepatitis Delta/aislamiento & purificación , Virus de la Hepatitis Delta/patogenicidad , Humanos , Interferones/uso terapéutico , Cirrosis Hepática/diagnóstico , Cirrosis Hepática/etnología , Cirrosis Hepática/etiología , Neoplasias Hepáticas/etnología , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/virología , Masculino , Características de la Residencia/estadística & datos numéricos , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Carga Viral/métodos , Carga Viral/estadística & datos numéricos , Viremia/diagnóstico , Viremia/etnologíaRESUMEN
BACKGROUND: Chronic hepatitis delta virus (HDV) infection causes severe liver disease which often leads to cirrhosis and hepatocellular carcinoma (HCC). Aim of this study was to establish the disease severity and prognostic factors for disease outcome by analysing frequencies of clinical events and their correlation with baseline virological and biochemical parameters as well as interferon and nucleos(t)ide analogue treatment choice. METHODS: We studied a single-centre cohort of 49 anti-HDAg-positive patients with HBsAg persistence for at least 6 months. Virological and biochemical parameters, interferon and nucleos(t)ide analogue treatment choice as well as clinical events during follow-up were analysed by retrospective chart review (mean follow-up time 3 years, range 0.25-7.67 years). RESULTS: Severe clinical events occurred in 11/49 hepatitis D patients, including HCC (8/49), death (8/49) or liver transplantation (2/49). HCCs only occurred secondary to liver cirrhosis and their event rates in this cohort of hepatitis D patients did not differ from a matched HBV mono-infected cohort with comparable frequency of liver cirrhosis. A stepwise multivariate logistic regression revealed low platelet count (p = 0. 0290) and older age (p = 0.0337) correlating most strongly with overall clinical events, while serum HDV RNA positivity at baseline did not correlate with any clinical outcome. Interferon-free but not nucleos(t)ide analogue-free patient care correlated with the occurrence of HCC at logistic regression, although only 3/18 interferon-treated patients demonstrated repeatedly negative HDV PCR results post therapy. CONCLUSIONS: Our data indicate that progressive liver disease at baseline plays a major role as predictive factor for overall clinical outcome of hepatitis D patients. In particular, HCC risk may not be underestimated in hepatitis D virus RNA negative hepatitis D patients with advanced liver fibrosis.
Asunto(s)
Carcinoma Hepatocelular/epidemiología , Coinfección/epidemiología , Hepatitis B Crónica/epidemiología , Hepatitis D Crónica/epidemiología , Cirrosis Hepática/epidemiología , Neoplasias Hepáticas/epidemiología , Carcinoma Hepatocelular/mortalidad , Carcinoma Hepatocelular/virología , Estudios de Cohortes , Coinfección/complicaciones , Coinfección/tratamiento farmacológico , Femenino , Alemania/epidemiología , Antígenos de Superficie de la Hepatitis B/sangre , Virus de la Hepatitis B/genética , Virus de la Hepatitis B/aislamiento & purificación , Hepatitis B Crónica/complicaciones , Hepatitis B Crónica/tratamiento farmacológico , Hepatitis D Crónica/complicaciones , Hepatitis D Crónica/tratamiento farmacológico , Virus de la Hepatitis Delta/genética , Virus de la Hepatitis Delta/aislamiento & purificación , Antígenos de Hepatitis delta/sangre , Humanos , Interferones/uso terapéutico , Cirrosis Hepática/virología , Neoplasias Hepáticas/mortalidad , Neoplasias Hepáticas/virología , Trasplante de Hígado , Estudios Longitudinales , Masculino , Morbilidad , Nucleósidos/uso terapéutico , Estudios RetrospectivosRESUMEN
BACKGROUND: Chronic hepatitis delta is a severe liver disease with rapid progression to cirrhosis. The impact of hepatitis delta virus (HDV)-RNA on disease progression and interferon treatment in a real-world cohort has been barely explored. AIM: To assess the development of clinical events in a cohort of chronic hepatitis delta patients according to the presence or absence of HDV-RNA METHODS: Multicentre study at four academic hospitals in Spain included anti-HDV-positive patients with compensated liver disease with a follow-up ≥12 months. RESULTS: Among 2888 HBsAg-positive subjects, 151 (5.2%) tested positive for anti-HDV, and 118 were included (58% men; median age, 49 years; 73% detectable HDV-RNA and 30% cirrhosis, most often in subjects with HDV-RNA). After a median follow-up of 8 years, subjects with initially detectable HDV-RNA were more prone to developing cirrhosis (31% vs 0%, P = .002) and/or liver decompensation (28% vs 3%, P = .019). Mortality rate was 0.44 per 1000 person-months. The probability of a clinical event was 6%, 25%, and 80% according to initial baseline-event-anticipation score. HDV-RNA became undetectable in 21 (24%) subjects either due to interferon or spontaneously (48% vs 52%, P = .29). Liver decompensation was reduced in interferon-treated patients (13% vs 38%, P = .026). CONCLUSIONS: Subjects with persistently positive HDV-RNA had a worse prognosis in terms of clinical events. Baseline-event-anticipation score is useful in predicting the risk of developing liver decompensation and hepatocellular carcinoma. Interferon was beneficial in reducing liver decompensation, even in the absence of virological response.
Asunto(s)
Hepatitis D Crónica/diagnóstico , Hepatitis D Crónica/epidemiología , Virus de la Hepatitis Delta , Viremia/epidemiología , Adulto , Anciano , Estudios de Cohortes , Progresión de la Enfermedad , Femenino , Estudios de Seguimiento , Hepatitis D Crónica/tratamiento farmacológico , Hepatitis D Crónica/patología , Virus de la Hepatitis Delta/fisiología , Humanos , Interferones/uso terapéutico , Fallo Hepático/tratamiento farmacológico , Fallo Hepático/epidemiología , Fallo Hepático/virología , Masculino , Persona de Mediana Edad , Pronóstico , España/epidemiología , Factores de Tiempo , Viremia/tratamiento farmacológicoRESUMEN
Chronic delta hepatitis is the most severe form of viral hepatitis affecting nearly 65 million people worldwide. Individuals with this devastating illness are at higher risk for developing cirrhosis and hepatocellular carcinoma. Delta virus is a defective RNA virus that requires hepatitis B surface antigen for propagation in humans. Infection can occur in the form of a co-infection with hepatitis B, which can be self-limiting, vs superinfection in a patient with established hepatitis B infection, which often leads to chronicity in majority of cases. Current noninvasive tools to assess for advanced liver disease have limited utility in delta hepatitis. Guidelines recommend treatment with pegylated interferon, but this is limited to patients with compensated disease and is efficacious in about 30% of those treated. Due to limited treatment options, novel agents are being investigated and include entry, assembly and export inhibitors of viral particles in addition to stimulators of the host immune response. Future clinical trials should take into consideration the interaction of hepatitis B and hepatitis D as suppression of one virus can lead to the activation of the other. Also, surrogate markers of treatment efficacy have been proposed.
Asunto(s)
Antivirales/uso terapéutico , Coinfección/tratamiento farmacológico , Hepatitis B Crónica/tratamiento farmacológico , Hepatitis D Crónica/tratamiento farmacológico , Sobreinfección/tratamiento farmacológico , Terapias en Investigación/métodos , Antivirales/farmacología , Coinfección/epidemiología , Coinfección/virología , Quimioterapia Combinada/métodos , Carga Global de Enfermedades , Antígenos de Superficie de la Hepatitis B/inmunología , Antígenos de Superficie de la Hepatitis B/metabolismo , Virus de la Hepatitis B/inmunología , Virus de la Hepatitis B/patogenicidad , Hepatitis B Crónica/epidemiología , Hepatitis B Crónica/virología , Hepatitis D Crónica/epidemiología , Hepatitis D Crónica/virología , Virus de la Hepatitis Delta/inmunología , Virus de la Hepatitis Delta/patogenicidad , Humanos , Interferón-alfa/farmacología , Interferón-alfa/uso terapéutico , Lipopéptidos/farmacología , Lipopéptidos/uso terapéutico , Transportadores de Anión Orgánico Sodio-Dependiente/antagonistas & inhibidores , Transportadores de Anión Orgánico Sodio-Dependiente/metabolismo , Piperidinas/farmacología , Piperidinas/uso terapéutico , Piridinas/farmacología , Piridinas/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Literatura de Revisión como Asunto , Sobreinfección/epidemiología , Sobreinfección/virología , Simportadores/antagonistas & inhibidores , Simportadores/metabolismo , Resultado del Tratamiento , Ensamble de Virus/efectos de los fármacos , Internalización del Virus/efectos de los fármacosRESUMEN
Chronic hepatitis D (CHD) results from an infection with the hepatitis B virus and hepatitis D virus (HDV). CHD is the most severe form of human viral hepatitis. Current treatment options consist of interferon alfa, which is effective only in a minority of patients. Study of HDV molecular virology has resulted in new approaches entering clinical trials, with phase-3 studies the most advanced. These include the entry inhibitor bulevirtide, the nucleic acid polymer REP 2139-Ca, the farnesyltransferase inhibitor lonafarnib, and pegylated interferon lambda. This article summarizes the available data on these emerging therapeutics.
Asunto(s)
Coinfección/tratamiento farmacológico , Virus de la Hepatitis B/efectos de los fármacos , Hepatitis D Crónica/tratamiento farmacológico , Virus de la Hepatitis Delta/efectos de los fármacos , Interferón-alfa/uso terapéutico , Polietilenglicoles/uso terapéutico , Antivirales/uso terapéutico , Ensayos Clínicos Fase III como Asunto , Drogas en Investigación/farmacología , Drogas en Investigación/uso terapéutico , Femenino , Virus de la Hepatitis B/aislamiento & purificación , Hepatitis B Crónica/diagnóstico , Hepatitis B Crónica/tratamiento farmacológico , Hepatitis B Crónica/epidemiología , Hepatitis D Crónica/diagnóstico , Hepatitis D Crónica/epidemiología , Humanos , Masculino , Piperidinas/uso terapéutico , Pronóstico , Piridinas/uso terapéutico , Proteínas Recombinantes/uso terapéutico , Medición de Riesgo , Resultado del TratamientoRESUMEN
The clinical outcome of hepatitis B virus (HBV) infection may be related to host and viral genetic factors, as well as to the type of infection (monoinfection and coinfection). To analyze the distribution/combination of HBV/hepatitis D virus (HDV) genotypes and the associated clinical characteristics, 409 serum samples from patients with chronic HBV (94 of them coinfected by HDV) followed at the Viral Hepatitis Referral Center of Rio Branco, Brazil were enrolled. HBV DNA and HDV RNA were amplified, respectively, by polymerase chain reaction (PCR) and nested PCR using specific primers in the PreC/C region and the S gene, and by reverse-transcription PCR and seminested PCR using specific primers in the delta antigen region and sequenced. The proportion of women (56.1%) was significantly higher than males in this cohort ( P < 0.01). Women were significantly younger (39.8 years; 8-77 years) than males (44.7 years; 12-79 years; P < 0.01). Sixty-eight (18%) patients were infected with HBV-F genotype and 264 (69.8%) with HBV/non-F genotypes. Coinfection by HDV was detected in 23.9% (94 of 409) of this population and was more frequent in male (54.2%, 51 of 94) than in female patients (44.7%, 42 of 94; P = 0.015). HDV-3 was the most prevalent (88.9%) genotype. Almost 70% of HDV-3 coinfected patients were infected with HBV/non-F genotypes. Severe liver disease was diagnosed in 41 patients, 60.9% (25 of 41) of them coinfected with HDV. HBV/HDV coinfection was associated with male sex, age above 30 years, severe liver disease, and increased alanine aminotransferase levels. HBV/HDV-3 coinfection is associated with severe liver disease, in Rio Branco, Brazil.
Asunto(s)
Coinfección/complicaciones , Coinfección/virología , Genotipo , Hepatitis B Crónica/epidemiología , Hepatitis D Crónica/epidemiología , Hepatopatías/virología , Adolescente , Adulto , Anciano , Brasil/epidemiología , Niño , Coinfección/epidemiología , ADN Viral/genética , Femenino , Virus de la Hepatitis B/genética , Virus de la Hepatitis Delta/genética , Humanos , Hígado/patología , Hígado/virología , Hepatopatías/epidemiología , Masculino , Persona de Mediana Edad , Filogenia , Prevalencia , Factores de Riesgo , Adulto JovenRESUMEN
Hepatitis delta virus (HDV) is a defective RNA virus that depends on the presence of hepatitis B virus (HBV) for the creation of new virions and propagation of the infection to hepatocytes. Chronic infection with HDV is usually associated with a worsening of HBV infection, leading more frequently to cirrhosis, increased risk of liver decompensation and hepatocellular carcinoma (HCC) occurrence. In spite of a progressive declining prevalence of both acute and chronic HDV infection observed over several years, mainly due to increased global health policies and mass vaccination against HBV, several European countries have more recently observed stable HDV prevalence mainly due to migrants from non-European countries. Persistent HDV replication has been widely demonstrated as associated with cirrhosis development and, as a consequence, development of liver decompensation and occurrence of HCC. Several treatment options have been attempted with poor results in terms of HDV eradication and improvement of long-term prognosis. A global effort is deemed urgent to enhance the models already existing as well as to learn more about HDV infection and correlated tumourigenesis mechanisms.
Asunto(s)
Carcinoma Hepatocelular/epidemiología , Hepatitis D/epidemiología , Hepatitis D/prevención & control , Virus de la Hepatitis Delta/fisiología , Neoplasias Hepáticas/epidemiología , Carcinoma Hepatocelular/virología , Hepatitis D/virología , Hepatitis D Crónica/epidemiología , Hepatitis D Crónica/prevención & control , Hepatitis D Crónica/virología , Humanos , Neoplasias Hepáticas/virologíaRESUMEN
BACKGROUND/AIMS: Hepatitis D virus (HDV) is a defective RNA virus that is dependent on hepatitis B surface antigen (HBsAg) for transmission and replication. HDV significance arises from the possibility of poor prognosis of hepatitis B virus (HBV) infection. In Saudi Arabia, HDV prevalence varied from 8 to 32% before the HBV vaccination program and ranged from 0 to 14.7% after the vaccination program was started. The last study, performed in 2004, showed a prevalence of 8.6% in hospital-based HBV cases and 3.3% in healthy donors. The aim of this study was to investigate the prevalence and molecular characterization of HDV in chronic hepatitis B (CHB) patients at the King Abdulaziz University Hospital in Jeddah, Saudi Arabia by molecular and serological techniques. To the best of our knowledge, this is the first study to detect HDV at the molecular level in Saudi Arabia. PATIENTS AND METHODS: The study included samples from 182 CHB patients from Jeddah; 13 samples with HBsAg negative were excluded. Samples were tested for HDV-Ab, viral RNA by reverse transcriptase-polymerase chain reaction (RT-PCR) in the HDV L-Ag region and sequence analysis. RESULTS: The mean age of the participants was 44.36 years; 75.1% of the participants were Saudi nationals, 58% were males. Nine samples were positive for HDV-Ab and four were borderline; all were subjected to RT-PCR amplification. Three of the positive HDV-Ab cases and 1 borderline case were positive by RT-PCR. All the positive cases had HBV genotype D, and the positive RT-PCR cases were positive for HBV DNA. One of the HDV viremic samples was of genotype 1 by sequencing. The prevalence of HDV in the study was 7.7%, which was lower in Saudis (6.3%) than in non-Saudis (11.9%). CONCLUSION: HDV coinfection does not seem to have an effect on the clinical status of the recruited CHB cases in this study. More studies are needed to investigate the genetic diversity in other areas such as the southern parts of the Kingdom.
Asunto(s)
Anticuerpos Antihepatitis/sangre , Hepatitis B Crónica/virología , Hepatitis D Crónica/genética , Virus de la Hepatitis Delta/genética , Prevalencia , Adulto , Anciano , Anciano de 80 o más Años , Coinfección , Femenino , Variación Genética/genética , Genotipo , Hepatitis B/epidemiología , Antígenos de Superficie de la Hepatitis B/sangre , Virus de la Hepatitis B/genética , Hepatitis B Crónica/epidemiología , Hepatitis D Crónica/epidemiología , Humanos , Masculino , Persona de Mediana Edad , ARN Viral/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Arabia Saudita/epidemiologíaRESUMEN
OBJECTIVE: The study aimed to evaluate the prevalence and predictor factors for compensated advanced chronic liver disease (c-ACLD) in patients with hepatitis Delta virus (HDV) infection. METHODS: This cross-sectional study included consecutive HDV-infected patients defined by positive anti-HDV. Patients with hepatitis C coinfection, liver transplantation or presence of conditions that limit liver (LSM) or spleen stiffness measurement (SSM) were excluded. Blood tests, abdominal ultrasound, SSM and LSM by transient elastography (FibroScan®) were performed at the same day. Alcohol consumption was quantified using the AUDIT score and c-ACLD was defined by LSM ≥ 15 kPa performed by an experimented operator blinded for clinical and laboratory data. RESULTS: 101 patients were eligible and few patients were excluded due to negative anti-HDV (n = 7), hepatitis C coinfection (n = 2), liver transplantation (n = 10) and limitation for LSM or SSM (n = 5). Therefore, 77 patients [61% male, age = 43 (IQR,36-52) years] were included. The prevalence of c-ACLD was 57% (n = 44/77). Patients with c-ACLD had a higher rate of detectable HBV viral load (p = 0.039), higher levels of transaminases, GGT, alkaline phosphatases, total bilirubin and INR (p<0.001 for all), as well as lower platelet count and albumin levels (p>0.001 for both) compared to those without c-ACLD. Patients with c-ACLD had higher SSM [65.2 (IQR,33.8-75.0) vs 21.8 (16.5-32.0) kPa; p<0.001] and higher splenic volume [475 (IQR,311-746) vs 154 (112-283) cm3; p<0.001] compared to those without. Detectable HBV viral load (>10 UI/ml), alkaline phosphatase (per IU/L) and GGT levels (per IU/L) were independently associated with c-ACLD in all multivariate models. Splenic volume [per cm3,OR = 1.01 (95%CI,1.01-1.02);p = 0.002], SSM [per kPa, OR = 1.04 (1.01-1.07);p = 0.012] and splenomegaly [yes vs no,OR = 28.45 (4.42-182.95);p<0.001] were independently associated with c-ACLD. CONCLUSIONS: The prevalence of c-ACLD was high in patients with chronic HDV infection in western Amazon basin. HBV viral load, liver enzymes and splenic features can be used to predict severe liver disease in HDV-infected patients.
Asunto(s)
Hepatitis D Crónica/epidemiología , Hepatitis D Crónica/virología , Hepatopatías/virología , Adulto , Coinfección/epidemiología , Coinfección/virología , Estudios Transversales , Femenino , Hepacivirus/patogenicidad , Anticuerpos Antihepatitis/inmunología , Virus de la Hepatitis B/patogenicidad , Hepatitis B Crónica/epidemiología , Hepatitis B Crónica/virología , Hepatitis C/epidemiología , Hepatitis C/virología , Virus de la Hepatitis Delta/patogenicidad , Humanos , Hígado/virología , Pruebas de Función Hepática/métodos , Masculino , Persona de Mediana Edad , Prevalencia , Carga Viral/métodosRESUMEN
Viral liver diseases are frequent comorbidities and major contributors to death in HIV-positive individuals on antiretroviral therapy. Although cure of hepatitis C and control of hepatitis B with antivirals avert liver disease progression in most HIV-coinfected patients, the lack of satisfactory treatment for hepatitis delta virus (HDV) infection remains a major threat for developing cirrhosis and liver cancer in this population. In the European Union (EU) and North America, sexual contact has replaced injection drug use that has been the major transmission route for HDV in HIV-positive persons. PegIFNα is the only approved HDV therapy; however, sustained HDV-RNA clearance is achieved by less than 25%. The recent discovery of sodium taurocholate cotransporting polypeptide as the key hepatitis B virus (HBV) and HDV cell entry receptor has opened the door to a new therapeutic era. Indeed, promising results have been released using Myrcludex-B, a sodium taurocholate cotransporting polypeptide inhibitor. More encouraging are data with new classes of HDV blockers, such as prenylation inhibitors (i.e. lonafarnib) and nucleic acid polymers. At this time, sustained suppression of HDV replication is the primary goal of HDV therapy, as it is associated with normalization of liver enzymes and histological improvement. Of note, the use of specific antivirals for HDV must be given along with anti-HBV agents to prevent HBV rebounds following removal of viral interference. The lack of persistent forms of HDV-RNA could provide a unique opportunity for curing hepatitis delta, even without eliminating HBV circular covalently closed DNA. Ultimately, suppression of HDV replication along with hepatitis B surface antigen clearance once drugs are off would be the best reflect of hepatitis delta cure.
Asunto(s)
Infecciones por VIH/complicaciones , Hepatitis D Crónica/epidemiología , Cirrosis Hepática/epidemiología , Neoplasias Hepáticas/epidemiología , Antivirales/uso terapéutico , Transmisión de Enfermedad Infecciosa , Hepatitis D Crónica/complicaciones , Hepatitis D Crónica/tratamiento farmacológico , Hepatitis D Crónica/transmisión , Humanos , Interferón-alfa/uso terapéutico , Lipopéptidos/uso terapéutico , Cirrosis Hepática/complicaciones , Piperidinas/uso terapéutico , Piridinas/uso terapéutico , Respuesta Virológica SostenidaRESUMEN
BACKGROUND: The endemicity of hepatitis delta virus infection in Italy has decreased in the last decades. AIM: To evaluate the current epidemiology of chronic delta infection in Italy and to compare the present findings with the corresponding figures from the previous studies. METHODS: A cross-sectional study involving 16 referral centres scattered all over the country in 2014. RESULTS: Out of the 513 hepatitis B surface antigen-positive subjects enrolled, 61 (11.9%) were anti-delta positive, with a sex ratio (M/F) of 2.05. The majority (80.3%) of them was 50 years or older, while the proportion of subjects younger than 30 years of age was as low as 3.3%. No difference was detected by geographical area of residence. The presence of liver cirrhosis was diagnosed in 52.4% of cases. In comparison to previous studies, a further shift towards the oldest age groups and an increasing proportion of subjects having liver cirrhosis among all anti-delta-positive subjects are observed. CONCLUSIONS: Currently, hepatitis delta infection mostly affects old people who have an advanced but indolent liver disease, reflecting a survival effect. The defective hepatitis delta virus is near to disappear in the country, where it has been discovered in the second half of 70s.